JP2007505085A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505085A5 JP2007505085A5 JP2006525833A JP2006525833A JP2007505085A5 JP 2007505085 A5 JP2007505085 A5 JP 2007505085A5 JP 2006525833 A JP2006525833 A JP 2006525833A JP 2006525833 A JP2006525833 A JP 2006525833A JP 2007505085 A5 JP2007505085 A5 JP 2007505085A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- benzimidazol
- ylidene
- dihydro
- acetonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 amino, carboxy, aminocarbonyl Chemical group 0.000 claims 42
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 23
- GVAAUBDAYOGTMQ-UHFFFAOYSA-N acetonitrile;1h-benzimidazole Chemical compound CC#N.C1=CC=C2NC=NC2=C1 GVAAUBDAYOGTMQ-UHFFFAOYSA-N 0.000 claims 13
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- RRGGROIZKNSXNR-RELWKKBWSA-N tert-butyl 3-[[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]carbamoyl]pyrrolidine-1-carboxylate Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC(=O)C1CCN(C(=O)OC(C)(C)C)C1 RRGGROIZKNSXNR-RELWKKBWSA-N 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 3
- SEAQTHCVAGBRFY-INWYIAFRSA-N (2r,4s)-6-fluoro-2-methylspiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C([C@H](OC1=CC=C(F)C=C11)C)[C@@]21NC(=O)NC2=O SEAQTHCVAGBRFY-INWYIAFRSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 claims 2
- 229950010170 epalrestat Drugs 0.000 claims 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- WMASQBHSXPTQIJ-ZAFFBPSHSA-N (1r,5r,7r)-n-[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide Chemical compound N\1C2=CC=CC=C2N(CC)C/1=C(\C#N)C1=NC(NC(=O)[C@H]2[C@@]3([H])CNC[C@](O3)(O2)[H])=NC=C1C WMASQBHSXPTQIJ-ZAFFBPSHSA-N 0.000 claims 1
- WMASQBHSXPTQIJ-LVDSTPADSA-N (1s,5s,7s)-n-[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide Chemical compound N\1C2=CC=CC=C2N(CC)C/1=C(\C#N)C1=NC(NC(=O)[C@@H]2[C@]3([H])CNC[C@@](O3)(O2)[H])=NC=C1C WMASQBHSXPTQIJ-LVDSTPADSA-N 0.000 claims 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 1
- WAAPEIZFCHNLKK-UFBFGSQYSA-N (2s,4s)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide Chemical compound C([C@H](OC1=CC=C(F)C=C11)C(=O)N)[C@@]21NC(=O)NC2=O WAAPEIZFCHNLKK-UFBFGSQYSA-N 0.000 claims 1
- DDVNZPBCWLCHHP-CAPFRKAQSA-N (2z)-2-(3-ethyl-1h-benzimidazol-2-ylidene)-2-[2-(2-imidazol-1-ylethylamino)-5-methylpyrimidin-4-yl]acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NCCN1C=CN=C1 DDVNZPBCWLCHHP-CAPFRKAQSA-N 0.000 claims 1
- JFPZAMGLUXPGJQ-CAPFRKAQSA-N (2z)-2-(3-ethyl-1h-benzimidazol-2-ylidene)-2-[2-(3-pyrazol-1-ylpropylamino)pyrimidin-4-yl]acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(N=1)=CC=NC=1NCCCN1C=CC=N1 JFPZAMGLUXPGJQ-CAPFRKAQSA-N 0.000 claims 1
- YQZPLFKEVGBUBM-CAPFRKAQSA-N (2z)-2-(3-ethyl-1h-benzimidazol-2-ylidene)-2-[2-[2-(1h-imidazol-5-yl)ethylamino]-5-methylpyrimidin-4-yl]acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NCCC1=CNC=N1 YQZPLFKEVGBUBM-CAPFRKAQSA-N 0.000 claims 1
- LZYUNMYBEZQFTD-XDJHFCHBSA-N (2z)-2-(3-ethyl-1h-benzimidazol-2-ylidene)-2-[2-[2-(1h-imidazol-5-yl)ethylamino]pyrimidin-4-yl]acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(N=1)=CC=NC=1NCCC1=CNC=N1 LZYUNMYBEZQFTD-XDJHFCHBSA-N 0.000 claims 1
- ZDACKGNFEATCSO-XDJHFCHBSA-N (2z)-2-(3-ethyl-1h-benzimidazol-2-ylidene)-2-[2-[3-(1,2,4-triazol-1-yl)propylamino]pyrimidin-4-yl]acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(N=1)=CC=NC=1NCCCN1C=NC=N1 ZDACKGNFEATCSO-XDJHFCHBSA-N 0.000 claims 1
- XRWHEPGKBFENFV-XDJHFCHBSA-N (2z)-2-(3-ethyl-1h-benzimidazol-2-ylidene)-2-[5-methyl-2-(2-methylpropylamino)pyrimidin-4-yl]acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C1=NC(NCC(C)C)=NC=C1C XRWHEPGKBFENFV-XDJHFCHBSA-N 0.000 claims 1
- AURMLXSMQYFGKW-RELWKKBWSA-N (2z)-2-(3-ethyl-1h-benzimidazol-2-ylidene)-2-[5-methyl-2-(2-piperidin-1-ylethylamino)pyrimidin-4-yl]acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NCCN1CCCCC1 AURMLXSMQYFGKW-RELWKKBWSA-N 0.000 claims 1
- PTZQHCCTCVQRJR-HEHNFIMWSA-N (2z)-2-(3-ethyl-1h-benzimidazol-2-ylidene)-2-[5-methyl-2-(3-pyrazol-1-ylpropylamino)pyrimidin-4-yl]acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NCCCN1C=CC=N1 PTZQHCCTCVQRJR-HEHNFIMWSA-N 0.000 claims 1
- LFWFNXNKIKCCOT-CAPFRKAQSA-N (2z)-2-(3-ethyl-1h-benzimidazol-2-ylidene)-2-[5-methyl-2-(piperidin-4-ylamino)pyrimidin-4-yl]acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC1CCNCC1 LFWFNXNKIKCCOT-CAPFRKAQSA-N 0.000 claims 1
- RHSQSWWCNGUHFC-HEHNFIMWSA-N (2z)-2-(3-ethyl-1h-benzimidazol-2-ylidene)-2-[5-methyl-2-[(1-methylpiperidin-4-yl)amino]pyrimidin-4-yl]acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC1CCN(C)CC1 RHSQSWWCNGUHFC-HEHNFIMWSA-N 0.000 claims 1
- RBNRLRZYGUTKBO-CAPFRKAQSA-N (2z)-2-(3-ethyl-1h-benzimidazol-2-ylidene)-2-[5-methyl-2-[3-(1,2,4-triazol-1-yl)propylamino]pyrimidin-4-yl]acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NCCCN1C=NC=N1 RBNRLRZYGUTKBO-CAPFRKAQSA-N 0.000 claims 1
- VCIMMQBMHZWKFT-OQKWZONESA-N (2z)-2-(3-ethyl-1h-benzimidazol-2-ylidene)-2-[5-methyl-2-[3-(2-oxopyrrolidin-1-yl)propylamino]pyrimidin-4-yl]acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NCCCN1CCCC1=O VCIMMQBMHZWKFT-OQKWZONESA-N 0.000 claims 1
- BFZLBFGOLMHLFP-XDJHFCHBSA-N (2z)-2-[2-(cyclobutylamino)-5-methylpyrimidin-4-yl]-2-(3-ethyl-1h-benzimidazol-2-ylidene)acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC1CCC1 BFZLBFGOLMHLFP-XDJHFCHBSA-N 0.000 claims 1
- GSZIQJGZEVBYIZ-NBVRZTHBSA-N (2z)-2-[2-(cyclobutylamino)pyrimidin-4-yl]-2-(3-ethyl-1h-benzimidazol-2-ylidene)acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(N=1)=CC=NC=1NC1CCC1 GSZIQJGZEVBYIZ-NBVRZTHBSA-N 0.000 claims 1
- RYGLSICAFNZNMP-HEHNFIMWSA-N (2z)-2-[2-(cyclohexylamino)-5-methylpyrimidin-4-yl]-2-(3-ethyl-1h-benzimidazol-2-ylidene)acetonitrile Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC1CCCCC1 RYGLSICAFNZNMP-HEHNFIMWSA-N 0.000 claims 1
- VJSBFVAZJBHKHH-GHRIWEEISA-N (2z)-2-[2-(ethylamino)-5-methylpyrimidin-4-yl]-2-(3-ethyl-1h-benzimidazol-2-ylidene)acetonitrile Chemical compound CCNC1=NC=C(C)C(C(\C#N)=C/2N(C3=CC=CC=C3N\2)CC)=N1 VJSBFVAZJBHKHH-GHRIWEEISA-N 0.000 claims 1
- BMHZAHGTGIZZCT-LJQANCHMSA-N (4r)-2-[(4-bromo-2-fluorophenyl)methyl]-6-fluorospiro[isoquinoline-4,3'-pyrrolidine]-1,2',3,5'-tetrone Chemical compound C1([C@]2(C(NC(=O)C2)=O)C2=O)=CC(F)=CC=C1C(=O)N2CC1=CC=C(Br)C=C1F BMHZAHGTGIZZCT-LJQANCHMSA-N 0.000 claims 1
- YCVWINWKMLREOP-VUODPORTSA-N (4r)-n-[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]-1,3-thiazolidine-4-carboxamide Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC(=O)[C@@H]1CSCN1 YCVWINWKMLREOP-VUODPORTSA-N 0.000 claims 1
- YCVWINWKMLREOP-COYFKBPASA-N (4s)-n-[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]-1,3-thiazolidine-4-carboxamide Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC(=O)[C@H]1CSCN1 YCVWINWKMLREOP-COYFKBPASA-N 0.000 claims 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 1
- ZGGNPKDLUKSQGX-RELWKKBWSA-N 1-acetyl-n-[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]piperidine-4-carboxamide Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC(=O)C1CCN(C(C)=O)CC1 ZGGNPKDLUKSQGX-RELWKKBWSA-N 0.000 claims 1
- QCCHBHSAIQIQGO-UHFFFAOYSA-N 2,7-difluorospiro[fluorene-9,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2C2=CC=C(F)C=C2C21NC(=O)NC2=O QCCHBHSAIQIQGO-UHFFFAOYSA-N 0.000 claims 1
- NRKMCUJASWHRQT-UHFFFAOYSA-N 2-(1,3-dihydrobenzimidazol-2-ylidene)-2-[5-methyl-2-[3-(2-oxopyrrolidin-1-yl)propylamino]pyrimidin-4-yl]acetonitrile Chemical compound N1=C(C(C#N)=C2NC3=CC=CC=C3N2)C(C)=CN=C1NCCCN1CCCC1=O NRKMCUJASWHRQT-UHFFFAOYSA-N 0.000 claims 1
- HSQAVTQYJVNJDR-UHFFFAOYSA-N 2-(1-ethylbenzimidazol-2-yl)-2-[2-(furan-2-ylmethylamino)-5-methylpyrimidin-4-yl]acetonitrile Chemical compound N=1C2=CC=CC=C2N(CC)C=1C(C#N)C(C(=CN=1)C)=NC=1NCC1=CC=CO1 HSQAVTQYJVNJDR-UHFFFAOYSA-N 0.000 claims 1
- IKUFHLMBNSFBRO-UHFFFAOYSA-N 2-(1-ethylbenzimidazol-2-yl)-2-[2-[2-(1,2,4-triazol-1-yl)ethylamino]pyrimidin-4-yl]acetonitrile Chemical compound N=1C2=CC=CC=C2N(CC)C=1C(C#N)C(N=1)=CC=NC=1NCCN1C=NC=N1 IKUFHLMBNSFBRO-UHFFFAOYSA-N 0.000 claims 1
- AHDLPRPPIZJMEC-UHFFFAOYSA-N 2-(1H-benzimidazol-2-yl)-2-[2-(cyclopentylamino)pyrimidin-4-yl]acetonitrile 2-(1-ethylbenzimidazol-2-yl)-2-[6-methyl-2-(2-pyridin-3-ylethylamino)pyrimidin-4-yl]acetonitrile Chemical compound N#CC(c1nc2ccccc2[nH]1)c1ccnc(NC2CCCC2)n1.CCn1c(nc2ccccc12)C(C#N)c1cc(C)nc(NCCc2cccnc2)n1 AHDLPRPPIZJMEC-UHFFFAOYSA-N 0.000 claims 1
- HPNDCMCOYAJERV-UHFFFAOYSA-N 2-(1h-benzimidazol-2-yl)-2-[5-methyl-2-(2-pyridin-3-ylethylamino)pyrimidin-4-yl]acetonitrile Chemical compound N1=C(C(C#N)C=2NC3=CC=CC=C3N=2)C(C)=CN=C1NCCC1=CC=CN=C1 HPNDCMCOYAJERV-UHFFFAOYSA-N 0.000 claims 1
- BOIZRKNKILSBTB-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)acetonitrile Chemical compound N#CCC1=NC=CN1 BOIZRKNKILSBTB-UHFFFAOYSA-N 0.000 claims 1
- LJLUHLMXSWYIKS-UHFFFAOYSA-N 2-(6-chloropyrimidin-4-yl)-2-(1,3-dihydrobenzimidazol-2-ylidene)acetonitrile Chemical compound C1=NC(Cl)=CC(C(C#N)=C2NC3=CC=CC=C3N2)=N1 LJLUHLMXSWYIKS-UHFFFAOYSA-N 0.000 claims 1
- NMMDPTXPHURZBR-UHFFFAOYSA-N 2-[2-(cyclohexylamino)pyrimidin-4-yl]-2-(1-ethylbenzimidazol-2-yl)acetonitrile Chemical compound N=1C2=CC=CC=C2N(CC)C=1C(C#N)C(N=1)=CC=NC=1NC1CCCCC1 NMMDPTXPHURZBR-UHFFFAOYSA-N 0.000 claims 1
- FQRCAUUSVDRERL-UHFFFAOYSA-N 2-[2-(cyclohexylmethylamino)-5-methylpyrimidin-4-yl]-2-(1-ethylbenzimidazol-2-yl)acetonitrile Chemical compound N=1C2=CC=CC=C2N(CC)C=1C(C#N)C(C(=CN=1)C)=NC=1NCC1CCCCC1 FQRCAUUSVDRERL-UHFFFAOYSA-N 0.000 claims 1
- ZVHRVTZDDQMAJA-UHFFFAOYSA-N 2-[2-(cyclopentylamino)-5-methylpyrimidin-4-yl]-2-(1,3-diethylbenzimidazol-2-ylidene)acetonitrile Chemical compound CCN1C2=CC=CC=C2N(CC)C1=C(C#N)C(C(=CN=1)C)=NC=1NC1CCCC1 ZVHRVTZDDQMAJA-UHFFFAOYSA-N 0.000 claims 1
- ONTIOJUGXBWDJB-UHFFFAOYSA-N 2-[2-(cyclopentylamino)-5-methylpyrimidin-4-yl]-2-(1-ethylbenzimidazol-2-yl)acetonitrile Chemical compound N=1C2=CC=CC=C2N(CC)C=1C(C#N)C(C(=CN=1)C)=NC=1NC1CCCC1 ONTIOJUGXBWDJB-UHFFFAOYSA-N 0.000 claims 1
- DUZYLYSYBVQFFG-UHFFFAOYSA-N 2-[2-[2-[6-(dimethylamino)pyridin-3-yl]ethylamino]-5-methylpyrimidin-4-yl]-2-(1-ethylbenzimidazol-2-yl)acetonitrile Chemical compound N=1C2=CC=CC=C2N(CC)C=1C(C#N)C(C(=CN=1)C)=NC=1NCCC1=CC=C(N(C)C)N=C1 DUZYLYSYBVQFFG-UHFFFAOYSA-N 0.000 claims 1
- VAEWDFXXHLHBTG-UHFFFAOYSA-N 2-[2-[2-[6-(dimethylamino)pyridin-3-yl]ethylamino]pyrimidin-4-yl]-2-(1-ethylbenzimidazol-2-yl)acetonitrile Chemical compound N=1C2=CC=CC=C2N(CC)C=1C(C#N)C(N=1)=CC=NC=1NCCC1=CC=C(N(C)C)N=C1 VAEWDFXXHLHBTG-UHFFFAOYSA-N 0.000 claims 1
- TUWHXVNPMWRVKR-UHFFFAOYSA-N 2-[2-[3-(2-oxopyrrolidin-1-yl)propylamino]pyrimidin-4-yl]acetonitrile Chemical compound O=C1CCCN1CCCNC1=NC=CC(CC#N)=N1 TUWHXVNPMWRVKR-UHFFFAOYSA-N 0.000 claims 1
- YREIRIKJAMPPHC-UHFFFAOYSA-N 2-[3-[(3-nitrophenyl)methyl]-2,4,5-trioxoimidazolidin-1-yl]acetic acid Chemical compound O=C1C(=O)N(CC(=O)O)C(=O)N1CC1=CC=CC([N+]([O-])=O)=C1 YREIRIKJAMPPHC-UHFFFAOYSA-N 0.000 claims 1
- BUYWFAJWTSIACV-UHFFFAOYSA-N 2-[3-oxo-4-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]-1,4-benzothiazin-2-yl]acetic acid Chemical compound FC1=CC(F)=C2SC(CN3C4=CC=CC=C4SC(C3=O)CC(=O)O)=NC2=C1F BUYWFAJWTSIACV-UHFFFAOYSA-N 0.000 claims 1
- OVKXDANNQWXYKF-UHFFFAOYSA-N 2-methyloctanamide Chemical compound CCCCCCC(C)C(N)=O OVKXDANNQWXYKF-UHFFFAOYSA-N 0.000 claims 1
- BCSVCWVQNOXFGL-UHFFFAOYSA-N 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(C(F)(F)F)=CC=C2S1 BCSVCWVQNOXFGL-UHFFFAOYSA-N 0.000 claims 1
- XFVQELOCUVVHQJ-LTGZKZEYSA-N 4-acetyl-n-[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]morpholine-2-carboxamide Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC(=O)C1CN(C(C)=O)CCO1 XFVQELOCUVVHQJ-LTGZKZEYSA-N 0.000 claims 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- OCMDIGCLYKVBCG-UHFFFAOYSA-N C(C)N1C(=NC2=C1C=CC=C2)C(C#N)C2=NC(=NC=C2)NC(CCC)C.N2C(=NC1=C2C=CC=C1)C(C#N)C1=NC(=NC=C1)NCCC=1C=NC=CC1 Chemical compound C(C)N1C(=NC2=C1C=CC=C2)C(C#N)C2=NC(=NC=C2)NC(CCC)C.N2C(=NC1=C2C=CC=C1)C(C#N)C1=NC(=NC=C1)NCCC=1C=NC=CC1 OCMDIGCLYKVBCG-UHFFFAOYSA-N 0.000 claims 1
- QQSKDRYZCGEATQ-UHFFFAOYSA-N C(C)N1C(=NC2=C1C=CC=C2)C(C#N)C2=NC(=NC=C2C)N2CCN(CC2)CC.C(C)N2C(=NC1=C2C=CC=C1)C(C#N)C1=NC(=NC=C1)NCCCN1CCCC1 Chemical compound C(C)N1C(=NC2=C1C=CC=C2)C(C#N)C2=NC(=NC=C2C)N2CCN(CC2)CC.C(C)N2C(=NC1=C2C=CC=C1)C(C#N)C1=NC(=NC=C1)NCCCN1CCCC1 QQSKDRYZCGEATQ-UHFFFAOYSA-N 0.000 claims 1
- WTMJJHQKYSABSG-UHFFFAOYSA-N C(C)N1C(=NC2=C1C=CC=C2)C(C#N)C2=NC=NC(=C2)NCCC=2C=NC=CC2.C2(CCCCC2)CNC2=NC=CC(=N2)C(C#N)C2=NC1=C(N2CC)C=CC=C1 Chemical compound C(C)N1C(=NC2=C1C=CC=C2)C(C#N)C2=NC=NC(=C2)NCCC=2C=NC=CC2.C2(CCCCC2)CNC2=NC=CC(=N2)C(C#N)C2=NC1=C(N2CC)C=CC=C1 WTMJJHQKYSABSG-UHFFFAOYSA-N 0.000 claims 1
- XLKZQBLWBIBALQ-DIRYEVLESA-N C1(CC1)NC1=NC=C(C(=N1)C(C#N)C1=NC2=C(N1CC)C=CC=C2)C.C2(CCCCCC2)NC2=NC=CC(=N2)/C(/C#N)=C/2\NC1=C(N2CC)C=CC=C1 Chemical compound C1(CC1)NC1=NC=C(C(=N1)C(C#N)C1=NC2=C(N1CC)C=CC=C2)C.C2(CCCCCC2)NC2=NC=CC(=N2)/C(/C#N)=C/2\NC1=C(N2CC)C=CC=C1 XLKZQBLWBIBALQ-DIRYEVLESA-N 0.000 claims 1
- AIGGRJIAORLKIH-LSJACRKWSA-N C1(CC1)NC1=NC=CC(=N1)C(C#N)C1=NC2=C(N1CC)C=CC=C2.C(C)N2\C(\NC1=C2C=CC=C1)=C(/C#N)\C1=NC(=NC=C1)NCC(C)C Chemical compound C1(CC1)NC1=NC=CC(=N1)C(C#N)C1=NC2=C(N1CC)C=CC=C2.C(C)N2\C(\NC1=C2C=CC=C1)=C(/C#N)\C1=NC(=NC=C1)NCC(C)C AIGGRJIAORLKIH-LSJACRKWSA-N 0.000 claims 1
- ATGJTWBOHYSVAU-UHFFFAOYSA-N C1(CCCC1)NC1=NC(=CC(=N1)C(C#N)C1=NC2=C(N1CC)C=CC=C2)C.N2C(=NC1=C2C=CC=C1)C(C#N)C1=NC(=NC=C1)NC1CC1 Chemical compound C1(CCCC1)NC1=NC(=CC(=N1)C(C#N)C1=NC2=C(N1CC)C=CC=C2)C.N2C(=NC1=C2C=CC=C1)C(C#N)C1=NC(=NC=C1)NC1CC1 ATGJTWBOHYSVAU-UHFFFAOYSA-N 0.000 claims 1
- DVYNMRQNLSLKFK-UHFFFAOYSA-N C1(CCCC1)NC1=NC=C(C(=N1)C(C#N)=C1NC2=C(N1)C=CC=C2)C.C(C)N2C(=NC1=C2C=CC=C1)C(C#N)C1=NC(=NC=C1)NCCC1=NC=CC=C1 Chemical compound C1(CCCC1)NC1=NC=C(C(=N1)C(C#N)=C1NC2=C(N1)C=CC=C2)C.C(C)N2C(=NC1=C2C=CC=C1)C(C#N)C1=NC(=NC=C1)NCCC1=NC=CC=C1 DVYNMRQNLSLKFK-UHFFFAOYSA-N 0.000 claims 1
- KEUSIBFVBOPEAA-MLWJBJAVSA-N C1(CCCC1)NC1=NC=CC(=N1)C(C#N)C1=NC2=C(N1CC)C=CC=C2.C2(CCCCCC2)NC2=NC=C(C(=N2)/C(/C#N)=C/2\NC1=C(N2CC)C=CC=C1)C Chemical compound C1(CCCC1)NC1=NC=CC(=N1)C(C#N)C1=NC2=C(N1CC)C=CC=C2.C2(CCCCCC2)NC2=NC=C(C(=N2)/C(/C#N)=C/2\NC1=C(N2CC)C=CC=C1)C KEUSIBFVBOPEAA-MLWJBJAVSA-N 0.000 claims 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229940122254 Intermediate acting insulin Drugs 0.000 claims 1
- 102000016261 Long-Acting Insulin Human genes 0.000 claims 1
- 108010092217 Long-Acting Insulin Proteins 0.000 claims 1
- 229940100066 Long-acting insulin Drugs 0.000 claims 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229940126033 PPAR agonist Drugs 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims 1
- 229960002632 acarbose Drugs 0.000 claims 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 1
- WSLOHMLGIVSUPR-UHFFFAOYSA-N adn-138 Chemical compound C1COC2=CC(Cl)=CC3=C2N1C(=O)C31CC(=O)NC1=O WSLOHMLGIVSUPR-UHFFFAOYSA-N 0.000 claims 1
- 239000003288 aldose reductase inhibitor Substances 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001761 chlorpropamide Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229960004580 glibenclamide Drugs 0.000 claims 1
- 229960004346 glimepiride Drugs 0.000 claims 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims 1
- 229960001381 glipizide Drugs 0.000 claims 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 229950007327 imirestat Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 229960001110 miglitol Drugs 0.000 claims 1
- 229950002259 minalrestat Drugs 0.000 claims 1
- YACVASIXKRSGTN-HKOYGPOVSA-N n-[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]-2-(2-methoxyphenyl)acetamide Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC(=O)CC1=CC=CC=C1OC YACVASIXKRSGTN-HKOYGPOVSA-N 0.000 claims 1
- HJNJVRZSRAALSA-HKOYGPOVSA-N n-[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]-4-(4-methylpiperazin-1-yl)-4-oxobutanamide Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC(=O)CCC(=O)N1CCN(C)CC1 HJNJVRZSRAALSA-HKOYGPOVSA-N 0.000 claims 1
- CEFGKVRORWVCCX-LTGZKZEYSA-N n-[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]-4-(dimethylamino)butanamide Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C1=NC(NC(=O)CCCN(C)C)=NC=C1C CEFGKVRORWVCCX-LTGZKZEYSA-N 0.000 claims 1
- UKAIAZARSBVLSU-SLEBQGDGSA-N n-[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC(=O)C(C=C1)=CC=C1CN1CCN(C)CC1 UKAIAZARSBVLSU-SLEBQGDGSA-N 0.000 claims 1
- FPKOYZHEODENCK-HMMYKYKNSA-N n-[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]-4-methylmorpholine-2-carboxamide Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC(=O)C1CN(C)CCO1 FPKOYZHEODENCK-HMMYKYKNSA-N 0.000 claims 1
- PUOGYFZAYJWDGN-HAVVHWLPSA-N n-[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]pyrimidin-2-yl]-4-(4-methylpiperazin-1-yl)-4-oxobutanamide Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(N=1)=CC=NC=1NC(=O)CCC(=O)N1CCN(C)CC1 PUOGYFZAYJWDGN-HAVVHWLPSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- IQHXABCGSFAKPN-UHFFFAOYSA-N pyrrolidine-3-carboxamide Chemical compound NC(=O)C1CCNC1 IQHXABCGSFAKPN-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- LXANPKRCLVQAOG-NSHDSACASA-N sorbinil Chemical compound C12=CC(F)=CC=C2OCC[C@@]21NC(=O)NC2=O LXANPKRCLVQAOG-NSHDSACASA-N 0.000 claims 1
- 229950004311 sorbinil Drugs 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- YXRJIMQFASKYID-FCDQGJHFSA-N tert-butyl 3-[[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]carbamoyl]piperidine-1-carboxylate Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC(=O)C1CCCN(C(=O)OC(C)(C)C)C1 YXRJIMQFASKYID-FCDQGJHFSA-N 0.000 claims 1
- GIZPASHJIJCEHO-LKUDQCMESA-N tert-butyl 4-[2-[[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]amino]-2-oxoethyl]piperidine-1-carboxylate Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C(C(=CN=1)C)=NC=1NC(=O)CC1CCN(C(=O)OC(C)(C)C)CC1 GIZPASHJIJCEHO-LKUDQCMESA-N 0.000 claims 1
- RVEDNPISIWUILK-LTGZKZEYSA-N tert-butyl n-[2-[[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]amino]-2-oxoethyl]-n-methylcarbamate Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C1=NC(NC(=O)CN(C)C(=O)OC(C)(C)C)=NC=C1C RVEDNPISIWUILK-LTGZKZEYSA-N 0.000 claims 1
- WIOPFXDBYQKNBK-OQKWZONESA-N tert-butyl n-[4-[[4-[(z)-cyano-(3-ethyl-1h-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl]amino]-4-oxobutyl]carbamate Chemical compound N1C2=CC=CC=C2N(CC)\C1=C(/C#N)C1=NC(NC(=O)CCCNC(=O)OC(C)(C)C)=NC=C1C WIOPFXDBYQKNBK-OQKWZONESA-N 0.000 claims 1
- 229960002277 tolazamide Drugs 0.000 claims 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 claims 1
- 229960005371 tolbutamide Drugs 0.000 claims 1
- LUBHDINQXIHVLS-UHFFFAOYSA-N tolrestat Chemical compound OC(=O)CN(C)C(=S)C1=CC=CC2=C(C(F)(F)F)C(OC)=CC=C21 LUBHDINQXIHVLS-UHFFFAOYSA-N 0.000 claims 1
- 229960003069 tolrestat Drugs 0.000 claims 1
- SXONDGSPUVNZLO-UHFFFAOYSA-N zenarestat Chemical compound O=C1N(CC(=O)O)C2=CC(Cl)=CC=C2C(=O)N1CC1=CC=C(Br)C=C1F SXONDGSPUVNZLO-UHFFFAOYSA-N 0.000 claims 1
- 229950006343 zenarestat Drugs 0.000 claims 1
- 229950005346 zopolrestat Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03102741 | 2003-09-12 | ||
| PCT/EP2004/052137 WO2005026155A1 (en) | 2003-09-12 | 2004-09-10 | Benzimidazole acetonitriles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007505085A JP2007505085A (ja) | 2007-03-08 |
| JP2007505085A5 true JP2007505085A5 (enExample) | 2007-10-11 |
Family
ID=34306922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525833A Pending JP2007505085A (ja) | 2003-09-12 | 2004-09-10 | ベンゾイミダゾールアセトニトリル |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1667995A1 (enExample) |
| JP (1) | JP2007505085A (enExample) |
| AU (1) | AU2004272306A1 (enExample) |
| CA (1) | CA2534317A1 (enExample) |
| IL (1) | IL174135A0 (enExample) |
| NO (1) | NO20061614L (enExample) |
| WO (1) | WO2005026155A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005061519A1 (en) | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| US7550598B2 (en) | 2004-08-18 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN113281309B (zh) * | 2021-05-17 | 2022-03-01 | 深圳市罗湖区人民医院 | 一种毒死蜱、多菌灵、阿特拉津三合一检测方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1110957A1 (en) * | 1999-12-24 | 2001-06-27 | Applied Research Systems ARS Holding N.V. | Benzazole derivatives and their use as JNK modulators |
| KR100816769B1 (ko) * | 2000-09-06 | 2008-03-26 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 글리코겐 합성효소 키나아제 3의 억제제 |
-
2004
- 2004-09-10 EP EP04766767A patent/EP1667995A1/en not_active Withdrawn
- 2004-09-10 JP JP2006525833A patent/JP2007505085A/ja active Pending
- 2004-09-10 AU AU2004272306A patent/AU2004272306A1/en not_active Abandoned
- 2004-09-10 WO PCT/EP2004/052137 patent/WO2005026155A1/en not_active Ceased
- 2004-09-10 CA CA002534317A patent/CA2534317A1/en not_active Abandoned
-
2006
- 2006-03-06 IL IL174135A patent/IL174135A0/en unknown
- 2006-04-10 NO NO20061614A patent/NO20061614L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007505085A5 (enExample) | ||
| JP4870562B2 (ja) | 糖尿病の治療のためのスルホンアミド誘導体 | |
| DK2686310T5 (en) | Benzodioxan-INHIBITORERAFLEUKOTRIEN PRODUCTION | |
| CN116547278A (zh) | 杂环glp-1激动剂 | |
| JP2023546055A (ja) | ヘテロ環ｇｌｐ－１アゴニスト | |
| CA2575003C (en) | Potassium channel inhibitors | |
| US9662339B2 (en) | Benzodioxane inhibitors of leukotriene production for combination therapy | |
| RU2011151277A (ru) | Мостиковые производные спиро[2.4]гептана в качестве агонистов рецептора alx и/или fprl2 | |
| JP2007505083A5 (enExample) | ||
| RU2007100136A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| JP2011503194A5 (enExample) | ||
| JP2014525444A5 (enExample) | ||
| RU2016108753A (ru) | Ингибиторы ферментов | |
| RU2013117403A (ru) | Пиперидинил-замещенные лактамы как модуляторы gpr119 | |
| JP2016523911A5 (enExample) | ||
| TW201722920A (zh) | 新穎愛帕琳（ａｐｅｌｉｎ）受體促效劑及使用方法 | |
| EP3022202A1 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| WO2011025006A1 (ja) | Ｇｐｒ１１９作動薬 | |
| IL271036B2 (en) | Heterocyclic compounds containing nitrogen transitions, which inhibit romk channel activity, and the use of such compounds for the treatment of cardiovascular diseases | |
| JPWO2020201773A5 (enExample) | ||
| CN120957993A (zh) | 杂环glp-1激动剂 | |
| JPWO2021170109A5 (enExample) | ||
| AU2004272306A1 (en) | Benzimidazole acetonitriles | |
| RU2015144485A (ru) | Геминально-замещенные цианоэтилпиразолопиридоны в качестве ингибиторов janus киназ | |
| JPWO2019216294A5 (enExample) |